Assessment of the impact of rosiglitazone on circulating MDA level in patients with T2D using subgroup analysis
| Subgroup | Comparisons (n) | Mean (μmol/mL) (95% CI) | Z-value | P value | Test of heterogeneity | |
| I2 (%) | P value | |||||
| Overall | 8 | −0.47 (−0.93 to −0.01) | −2.01 | 0.04 | 82.1 | <0.05 |
| Dose (mg/day) | ||||||
| 4 | 5 | −0.38 (−1.04 to 0.28) | −3.3 | 0.25 | 88.9 | <0.05 |
| 8 | 3 | −0.56 (−0.98 to −0.14) | −2.7 | 0.008 | 11.43 | 0.32 |
| Duration (week) | ||||||
| ≤12 | 4 | −0.54 (−1.3 to 0.25) | −3.8 | 0.18 | 90.4 | <0.05 |
| >12 | 4 | −0.37 (−0.86 to 0.11) | −1.9 | 0.13 | 55.8 | 0.07 |
| Sample | ||||||
| Plasma | 4 | −0.18 (−0.68 to 0.30) | −0.75 | 0.45 | 71.7 | 0.014 |
| Serum | 4 | 0.74 (−1.4 to −0.07) | −5.5 | 0.03 | 80.3 | 0.002 |
| Gender | ||||||
| Female | 2 | −0.75 (−1.6 to 0.17) | −3.4 | 0.11 | 81.8 | 0.019 |
| Mix | 6 | −0.38 (−0.95 to 0.18) | −2.9 | 0.18 | 83.9 | <0.05 |
Mix: female plus male.
MDA, malondialdehyde; T2D, type 2 diabetes.